Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China ...
China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...
Illumina shareholders received a warning shot. In response to President Trump’s initial tariff measures, the Chinese ...
In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies ...
RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
Illumina (ILMN) said it is instituting an incremental approximately $100M cost reduction program for fiscal 2025. The company added, “These ...
7d
GlobalData on MSNChina bans Illumina sequencer imports as US trade war intensifiesGlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.
Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results